Balasubramanyam Seshan

841-870 (out of 1193)

Princeton Review Shares Hit New Low On Q4 Results

Shares of Princeton Review Inc. (REVU) touched a new 52-week low of $0.49 on Thursday, after reporting a wider-than-expected fourth quarter loss. The company also said it has has appointed John Connolly as interim president and chief executive officer, succeeding Michael Perik who has resigned to pursue other interests.

RC2 Shares Hit New High On Tomy Merger

Shares of RC2 Corp. (RCRC) touched a new more than 3-year high of $27.59 on Thursday, shortly after the Nikkei business daily first reported that Japan's Tomy Co. Ltd. and RC2 were in merger talks.

Spectrum Pharma Shares Hit New High on Q4 Results

Shares of Spectrum Pharmaceuticals, Inc. (SPPI) touched a new 52-week high of $7.60 on Thursday. The company posted a decline in fourth quarter earnings as last year period recorded stock warrant gains, but came ahead of Street view.

Starbucks, Green Mountain Sign Single Serve Coffee Deal

Starbucks Corp. (NASDAQ: SBUX) is taking on the fast-growing single serve market, by teaming with Green Mountain Coffee Roasters, Inc. (NASDAQ: GMCR) that holds a dominant share of the U.S. market at about 80 percent owing to several patents surrounding its K-cup.

Focus Media Shares Hit New High On Q4 Results

Shares of Focus Media Holding Ltd. (FMCN) touched a new 52-week high of $30.27 on Wednesday. The company reported Tuesday higher fourth quarter adjusted earnings as revenue in LCD display (including the movie theater network), in-store and poster frame business increased 45 percent.

Genzyme Shares Hit New High Again

Genzyme Corp. (NASDAQ: GENZ) said Monday that its board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi-Aventis SA (NYSE: SNY) and to tender their shares into the revised offer. The shares of Genzyme touched a new 52-week high of $76.09 on Wednesday.

Velti Initiated At 'Buy': Jefferies

Jefferies & Co. initiated its rating on shares of Velti Plc (NASDAQ: VELT) with a buy rating and a price target of $16.50. The company's unique advantage is that it offers customers the ability to deploy mobile marketing campaigns on a global basis, the brokerage said.

Talecris Biotherapeutics Shares Hit New High

Shares of Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) touched a new 52-week high of $25.80 on Tuesday. The biotechnology company's stock has been rising since Thursday when it received orphan drug designation from the European Commission for the development of Plasmin, derived from human plasma, to treat acute peripheral arterial occlusion.

iPad 2 Keeps Apple Ahead

Barclays Capital said its sales estimates for iPad 2 are likely conservative for Apple Inc.'s March quarter because of early shipment date. The brokerage still expects that competitors will find it tougher to compete with Apple in tablets than in phones given the integration of iTunes and Apple’s expertise in design and battery life.

Single Serve Coffee Is a Good Bet for Starbucks

Single serve coffee represents a meaningful opportunity for Starbucks Corp. (NASDAQ: SBUX) as it is a $4 billion a year market globally with US growing rapidly from its current base of about $100 million, according to RBC Capital Markets.

Xyratex's Hard Disk Drive Segment Under Pressure: Analyst

Xyratex Ltd.'s (NASDAQ: XRTX) hard disk drive-related business segment Storage Infrastructure is currently under pressure from continued, weak demand and excess supply for 2.5-inch (i.e. notebook) drives, according to RBC Capital Markets.

Global Tablet Revenue to Grow to $70 bln by 2014

RBC Capital Markets expects tablet market to reach 185 million units in calendar 2014, up 83 percent compound annual growth rate (CAGR) from 17 million in calendar 2010. RBC Capital forecasts global tablet revenue to increase from $11 billion in calendar 2010 to nearly $70 billion in calendar 2014.

IBM Analyst Day Likely to Focus on 2015 Roadmap

IBM would be hosting its Analyst Day today at its Thomas J. Watson Research Center in Yorktown Heights, New York at 10 am EST that is likely to focus on 2015 roadmap, according to Barclays Capital.

Genzyme Shares Hit New High as Board Recommends Sanofi's Revised Offer

Shares of Genzyme Corp. (NASDAQ: GENZ) touched a new 52-week high of $75.90 on Monday. The biotechnology firm's board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi-Aventis SA (NYSE: SNY) and to tender their shares into the revised offer.

TomoTherapy Shares Hit New High On Accuray Merger

Shares of TomoTherapy Inc. (NASDAQ: TOMO) touched a new 52-week high of $4.70 on Monday after it agreed to be acquired by Accuray Inc. (NASDAQ: ARAY) for $4.80 a share in cash and stock or a total of about $277 million.

Any Export in Storm -- Potential for LNG Exports

U.S. Federal Energy Regulatory Commission (FERC) has exclusive authority under the Natural Gas Act to authorize the siting of facilities for imports or exports of liquefied natural gas (LNG), according to FBR Capital Markets.

Altera Shares Hit New High

Shares of Altera Corp. (NASDAQ: ALTR) touched a new 52-week high of $45 on Friday. The compay said March 1 that it still predicts first quarter sales to decline 1 percent to 5 percent sequentially.

Pages